Published in Int J Radiat Oncol Biol Phys on May 01, 2006
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med (2009) 1.53
Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer. Semin Radiat Oncol (2009) 1.20
Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. Neoplasia (2007) 1.12
18F-FDG PET/CT imaging in oncology. Ann Saudi Med (2011) 1.08
Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. J Oncol (2009) 1.06
A novel PET tumor delineation method based on adaptive region-growing and dual-front active contours. Med Phys (2008) 1.02
FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol (2008) 1.02
Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol (2008) 0.99
PET/CT staging followed by Intensity-Modulated Radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol (2007) 0.97
Recent advances in image-guided radiotherapy for head and neck carcinoma. J Oncol (2009) 0.96
Interobserver variation in clinical target volume and organs at risk segmentation in post-parotidectomy radiotherapy: can segmentation protocols help? Br J Radiol (2012) 0.94
Nonrigid image registration for head and neck cancer radiotherapy treatment planning with PET/CT. Int J Radiat Oncol Biol Phys (2007) 0.94
18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters. Radiat Oncol (2010) 0.90
Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target. Eur J Nucl Med Mol Imaging (2008) 0.86
PET in face and neck tumours. Cancer Imaging (2006) 0.83
PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging (2007) 0.83
Interobserver and intermodality variability in GTV delineation on simulation CT, FDG-PET, and MR Images of Head and Neck Cancer. Jacobs J Radiat Oncol (2014) 0.82
Size-dependent thresholding as an optimal method for tumor volume delineation on positron emission tomography-computed tomography: A Phantom study. Indian J Nucl Med (2011) 0.80
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer (2010) 0.79
Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers. World J Radiol (2014) 0.79
1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging (2006) 0.78
Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations. Cancer Imaging (2007) 0.77
A quantitative comparison of gross tumour volumes delineated on [18F]-FDG PET-CT scan and CECT scan in head and neck cancers. Indian J Nucl Med (2012) 0.77
(18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. Eur J Nucl Med Mol Imaging (2016) 0.76
FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer. J Nucl Med Radiat Ther (2012) 0.75
Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer. J Natl Compr Canc Netw (2015) 0.75
Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer. J Radiat Res (2013) 0.75
Biological imaging in clinical oncology-introduction. Int J Clin Oncol (2016) 0.75
Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers. Int J Clin Oncol (2016) 0.75
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol (2002) 4.56
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys (2004) 3.42
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys (2007) 2.80
Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys (2010) 2.69
How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 2.46
Radiation-associated liver injury. Int J Radiat Oncol Biol Phys (2010) 2.39
Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol (2004) 2.27
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging (2010) 2.18
Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 2.15
Commissioning of the discrete spot scanning proton beam delivery system at the University of Texas M.D. Anderson Cancer Center, Proton Therapy Center, Houston. Med Phys (2010) 2.09
Accelerator beam data commissioning equipment and procedures: report of the TG-106 of the Therapy Physics Committee of the AAPM. Med Phys (2008) 1.89
Four-dimensional cone beam CT with adaptive gantry rotation and adaptive data sampling. Med Phys (2007) 1.84
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2012) 1.77
The M. D. Anderson proton therapy system. Med Phys (2009) 1.75
Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.75
Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys (2010) 1.74
Reducing metal artifacts in cone-beam CT images by preprocessing projection data. Int J Radiat Oncol Biol Phys (2006) 1.65
Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol (2004) 1.63
Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J Cardiovasc Magn Reson (2005) 1.58
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Intradural spinal vein enlargement in craniospinal hypotension. AJNR Am J Neuroradiol (2005) 1.47
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol (2002) 1.47
Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys (2003) 1.45
Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in Wisconsin. Urology (2013) 1.42
EGFRvIII expression in squamous cell carcinoma of the skin. JAMA Dermatol (2013) 1.39
Tools for consensus analysis of experts' contours for radiotherapy structure definitions. Radiother Oncol (2010) 1.36
Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration. Phys Med Biol (2012) 1.34
Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer (2003) 1.33
A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties. Int J Radiat Oncol Biol Phys (2011) 1.31
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol (2010) 1.31
Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. Int J Radiat Oncol Biol Phys (2008) 1.26
Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol (2003) 1.25
Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys (2009) 1.25
Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. Radiology (2003) 1.22
Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys (2008) 1.22
Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol Biol Phys (2004) 1.19
Experimental characterization of the low-dose envelope of spot scanning proton beams. Phys Med Biol (2010) 1.16
Interfractional variations in patient setup and anatomic change assessed by daily computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.15
Monte Carlo investigation of the low-dose envelope from scanned proton pencil beams. Phys Med Biol (2010) 1.15
Direct aperture optimization-based intensity-modulated radiotherapy for whole breast irradiation. Int J Radiat Oncol Biol Phys (2007) 1.14
The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose. J Magn Reson Imaging (2003) 1.12
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys (2011) 1.11
Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys (2002) 1.10
Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med (2010) 1.09
Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain. Magn Reson Med (2004) 1.08
Respiratory organ motion and dosimetric impact on breast and nodal irradiation. Int J Radiat Oncol Biol Phys (2010) 1.08
Role of the angiotensin II type-2 receptor in radiation nephropathy. Transl Res (2007) 1.07
1998-1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I-II breast cancer. Int J Radiat Oncol Biol Phys (2005) 1.04
Is α/β for breast cancer really low? Radiother Oncol (2011) 1.03
Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys (2008) 1.03
LiF TLD-100 as a dosimeter in high energy proton beam therapy--can it yield accurate results? Med Dosim (2009) 1.03
Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys (2006) 1.02
Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol (2009) 1.01
Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.00
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther (2006) 1.00
An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications. Cancers (Basel) (2012) 1.00
Cardiac injury after 10 gy total body irradiation: indirect role of effects on abdominal organs. Radiat Res (2013) 0.99
Dynamically accumulated dose and 4D accumulated dose for moving tumors. Med Phys (2012) 0.99
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol (2006) 0.98
Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys (2004) 0.98
Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol (2013) 0.98
Intra- and interfractional variations for prone breast irradiation: an indication for image-guided radiotherapy. Int J Radiat Oncol Biol Phys (2007) 0.98
Dosimetric impact of intrafraction motion for compensator-based proton therapy of lung cancer. Phys Med Biol (2008) 0.98
The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys (2003) 0.97
Improved critical structure sparing with biologically based IMRT optimization. Med Phys (2009) 0.97
Irradiation of varying volumes of rat lung to same mean lung dose: a little to a lot or a lot to a little? Int J Radiat Oncol Biol Phys (2008) 0.97
Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. Int J Radiat Oncol Biol Phys (2011) 0.96
Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2005) 0.96
Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer (2005) 0.96
Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope (2005) 0.95
An on-line replanning method for head and neck adaptive radiotherapy. Med Phys (2009) 0.95
Status of postmastectomy radiotherapy in the United States: a patterns of care study. Int J Radiat Oncol Biol Phys (2004) 0.95
Automated registration of large deformations for adaptive radiation therapy of prostate cancer. Med Phys (2009) 0.94
Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis. Int J Radiat Oncol Biol Phys (2007) 0.94
An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int J Radiat Oncol Biol Phys (2006) 0.94
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol (2009) 0.93
Preliminary evaluation of multifield and single-field optimization for the treatment planning of spot-scanning proton therapy of head and neck cancer. Med Phys (2013) 0.93
Scatter kernel estimation with an edge-spread function method for cone-beam computed tomography imaging. Phys Med Biol (2008) 0.93
Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy. Int J Radiat Oncol Biol Phys (2012) 0.92
An on-line replanning scheme for interfractional variations. Med Phys (2008) 0.92
Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys (2003) 0.92
Report of AAPM Therapy Physics Committee Task Group 74: in-air output ratio, Sc, for megavoltage photon beams. Med Phys (2009) 0.92
Equivalence of the linear-quadratic and two-lesion kinetic models. Phys Med Biol (2002) 0.92
Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate. Phys Med Biol (2011) 0.91